Table 4 Use of anticoagulants in acute ischemic stroke patients with and without atrial fibrillation by regions

With atrial fibrillation

n = 429

n = 204

n = 143

n = 61

n = 21

Anticoagulants

189 (44.1)

93 (45.6)

52 (36.4)

33 (54.1)

11 (52.4)

0.08

 Heparin

5 (1.2)

1 (0.5)

2 (1.4)

2 (3.3)

0

0.264

 LMWH

84 (19.6)

40 (19.6)

21 (14.7)

19 (31.1)

4 (19.0)

0.068

 Warfarin

72 (16.8)

43 (21.1)

3 (2.1)

18 (29.5)

8 (38.1)

< 0.001

 NOAC

57 (13.3)

27 (13.2)

28 (19.6)

2 (3.3)

0

0.001

 Fondaparinux sodium

1 (0.2)

0

0

1 (1.6)

0

0.191

OR (95% CI)

 Crude

Ref.

0.68 (0.44–1.06)

1.41 (0.79–2.50)

1.31 (0.53–3.23)

 Adjusted

Ref.

0.65 (0.41–1.04)

1.42 (0.77–2.61)

1.21 (0.47–3.12)

Without atrial fibrillation

n = 9544

n = 4602

n = 2409

n = 1963

n = 570

Anticoagulants

874 (9.2)

387 (8.4)

169 (7.0)

278 (14.2)

40 (7.0)

< 0.001

 Heparin

144 (1.5)

47 (1.0)

20 (0.8)

74 (3.8)

3 (0.5)

< 0.001

 LMWH

629 (6.6)

293 (6.4)

130 (5.4)

188 (9.6)

18 (3.2)

< 0.001

 Warfarin

112 (1.2)

59 (1.3)

8 (0.3)

22 (1.1)

23 (4.0)

< 0.001

 NOAC

45 (0.5)

25 (0.5)

14 (0.6)

5 (0.3)

1 (0.2)

0.280

 Fondaparinux sodium

1 (0.01)

0

1 (0.04)

0

0

0.518

OR (95% CI)

 Crude

Ref.

0.82 (0.68–0.99)*

1.80(1.53–2.12)**

0.82 (0.59–1.15)

 Adjusted

Ref.

0.78 (0.64–0.95)*

1.62(1.36–1.92)**

0.76 (0.54–1.06)